LGMD2D Pt. 4, LGMD2D #4
UCLi005-A
General
Cell Line |
|
| hPSCreg name | UCLi005-A |
| Cite as: | UCLi005-A (RRID:CVCL_9S57) |
| Alternative name(s) |
LGMD2D Pt. 4, LGMD2D #4
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 22nd May 2019 |
| User feedback | |
Provider |
|
| Generator | University College London (UCL) |
| Owner | Dept of Cell and Developmental Biology |
| Distributors | |
External Databases |
|
| Cellosaurus | CVCL_9S57 |
| BioSamples | SAMEA4091959 |
| Wikidata | Q54989673 |
General Information |
|
| Publications | |
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 10-14 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
| Non-disease associated phenotypes |
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
External Databases (Donor) |
|
| BioSamples | SAMEA4091958 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | No |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Provide contact information of the holder of the original Donor Information Sheet: | |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | No |
| Contact information / weblink | |
| Alternatives to consent | |
| Alternative consent approval number | |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent pertain to a specific research project? | No |
| Details on restriction to research project | |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: | |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Contact data, institution, or website: | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | MTCC Biobank & Friedrich-Baur-Institut / NHS HRA NRES Committee London - Stanmore |
| Approval number | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | MTCC Biobank & Friedrich-Baur-Institut / NHS HRA NRES Committee London - Stanmore |
| Approval number | |
| Do you have obligations to third parties in regard to the use of the cell line? | Yes |
| Please describe: | MTCC Biobank notification |
| Further constraints on use | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Constraints for use or distribution | |
hIPSC Derivation
General |
|
| Source cell type |
A myoblast that differentiates into skeletal muscle fibers.
Synonyms
|
| Age of donor (at collection) | 10-14 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Is the used vector excisable? |
No |
| Absence of reprogramming vector(s)? |
No |
| Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| O2 Concentration | 5 % |
| Medium |
TeSR™ E8™
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|
||||
| SOX2 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
Morphology pictures
eb71c48cca238458a3e2dd9cf18f8c57.pdf
Morphology of undifferentiated LGMD2D iPSCs #4 grown without feeder layer cells in chemically defined media. Approximate passage number: 10.
Differentiation Potency
In vitro spontaneous differentiation
In vitro directed differentiation
| Marker | Expressed |
| MSX1 |
Yes |
In vitro spontaneous differentiation
| Marker | Expressed |
| MAP2 |
Yes |
| PAX6 |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.